protocolSection identificationModule nctId: NCT06267963, orgStudyIdInfo id: C4391010, secondaryIdInfos id: 2023-507074-40-00, type: REGISTRY, domain: CTIS (EU), briefTitle: A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-31, primaryCompletionDateStruct date: 2024-04-18, completionDateStruct date: 2024-04-18, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to learn about how much PF-07220060 will be taken up and processed by healthy male participants.The study is seeking for participants who:* are males aged 18 to 65 years and are healthy.* have Body mass index (BMI) between 17.5 and 30.5 kilograms/meter2* have a total body weight of at least 50 kilograms.The study consists of two groups. In group 1, participants will take one amount of PF-07220060 by mouth. In group 2, participants will take one amount by mouth and one amount as an injection through a vein at the study clinic.In group 1, participants will stay at the clinic site for up to 15 days. In group 2, the duration of participants' stay depends on the results of group 1.During their stays, participants will have their blood, urine, and feces collected by the study doctors several times. We will measure the level of PF-07220060 in participants' blood, urine, and feces samples. This will help to know how much the study medicine is getting taken up by the body. At the end of the study, participants will be contacted by phone to check in. Participants will be involved in this study for about 9 weeks from the screening until the follow-up., conditionsModule conditions: Healthy Participants, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ACTUAL, armsInterventionsModule interventions name: Oral [14C]PF-07220060, interventions name: Oral PF-07220060, interventions name: IV [14C] PF-07220060, outcomesModule primaryOutcomes measure: Cumulative recovery (%) of radioactivity in urine and feces (adjusted for vomitus, if any), expressed as a percent of total oral radioactive dose administered., primaryOutcomes measure: Amount of metabolites of [14C]PF-07220060 in plasma, urine, and feces., secondaryOutcomes measure: Dose normalized AUCinf of intravenous radiolabeled PF-07220060 in plasma (if data permit), secondaryOutcomes measure: The absolute oral bioavailability (F) of PF-07220060, secondaryOutcomes measure: The fraction of PF-07220060 dose absorbed (Fa), secondaryOutcomes measure: Number of participants with treatment emergent clinically significant laboratory abnormalities, secondaryOutcomes measure: Number of participants with treatment emergent clinically significant abnormal ECG measurements, secondaryOutcomes measure: Number of participants with treatment emergent clinically significant abnormal vital measurements, secondaryOutcomes measure: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs), secondaryOutcomes measure: Number of participants with treatment emergent clinically significant abnormal physical examination, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: PRA Health Sciences, city: Groningen, zip: 9728 NZ, country: Netherlands, geoPoint lat: 53.21917, lon: 6.56667, hasResults: False